Overview Dividends

(NVST) Envista Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29415F1049

Implants, Aligners, Imaging, Instruments, Materials

EPS (Earnings per Share)

EPS Growth (3y CAGR): -16.18%
EPS Trend (3y Corr): -50.9%

Last SUE: 0.56σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 0.50%
Revenue Trend (3y Corr): 12.7%

Last SUE: 1.59σ
Qual. Beats: 3

Risk via 10d forecast
Volatility	36.5%
Value at Risk 5%th	56.7%
Relative Tail Risk	-5.52%

Reward TTM
Sharpe Ratio	-0.05
Alpha	-21.78

Character TTM
Hurst Exponent	0.245
Beta	1.272
Beta Downside	1.141

Drawdowns 3y
Max DD	65.27%
Mean DD	42.26%
Median DD	50.71%

Description: NVST Envista Holdings November 07, 2025

Envista Holdings Corp (NVST) is a U.S.–based dental-technology company that designs, manufactures and sells a broad portfolio of products across two primary segments: Specialty Products & Technologies and Equipment & Consumables. The Specialty segment supplies implant systems, guided-surgery tools, biomaterials, prosthetics, orthodontic brackets, wires and digital orthodontic solutions, together with software suites (DTX Studio Implant, Lab, Clinic) under brands such as Nobel Biocare, Ormco and Damon. The Equipment & Consumables segment delivers digital imaging, endodontic, restorative, and infection-prevention supplies-including Dexis imaging units, Kerr bonding agents and CaviWipes-targeting dental offices, clinics and hospitals.

Key industry metrics that shape Envista’s outlook include: (1) the global dental market, projected to exceed $45 billion by 2027, driven by an aging population and increasing demand for cosmetic dentistry; (2) digital dentistry adoption, with implant-guided surgery and intra-oral scanners growing at ~12% CAGR, which directly benefits Envista’s software-enabled product lines; and (3) the company’s recent financial performance-FY 2023 revenue of $1.5 billion, a 6% YoY increase, and an operating margin of ~14%-suggesting modest scalability but also highlighting sensitivity to raw-material cost inflation and foreign-exchange volatility in its China operations.

For a deeper quantitative assessment, you may find the ValueRay platform’s detailed valuation model useful.

NVST Stock Overview

Market Cap in USD	3,149m
Sub-Industry	Health Care Equipment
IPO / Inception	2019-09-18
Return 12m vs S&P 500	-16.1%
Analyst Rating	3.29 of 5

NVST Dividends

Currently no dividends paid

NVST Growth Ratios

Metric	Value
CAGR 3y	-20.00%
CAGR/Max DD Calmar Ratio	-0.31
CAGR/Mean DD Pain Ratio	-0.47
Current Volume	1226.4k
Average Volume	1667k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (15.3m TTM) > 0 and > 6% of Revenue (6% = 157.3m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA -0.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 42.97% (prev 37.21%; Δ 5.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 300.1m > Net Income 15.3m (YES >=105%, WARN >=100%)

Net Debt (468.2m) to EBITDA (341.9m) ratio: 1.37 <= 3.0 (WARN <= 3.5)

Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (170.3m) change vs 12m ago -1.50% (target <= -2.0% for YES)

Gross Margin 55.37% (prev 53.69%; Δ 1.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 47.01% (prev 45.43%; Δ 1.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.09 (EBITDA TTM 341.9m / Interest Expense TTM 70.8m) >= 6 (WARN >= 3)

Altman Z'' 1.06

(A) 0.20 = (Total Current Assets 1.95b - Total Current Liabilities 821.7m) / Total Assets 5.64b

(B) -0.08 = Retained Earnings (Balance) -473.3m / Total Assets 5.64b

(D) -0.23 = Book Value of Equity -584.6m / Total Liabilities 2.55b

Total Rating: 1.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 57.18

1. Piotroski 5.50pt

2. FCF Yield 7.26%

3. FCF Margin 10.01%

4. Debt/Equity 0.52

5. Debt/Ebitda 1.37

6. ROIC - WACC (= -1.16)%

7. RoE 0.50%

8. Rev. Trend 12.66%

9. EPS Trend -50.87%

What is the price of NVST shares?

As of November 22, 2025, the stock is trading at USD 19.11 with a total of 1,226,360 shares traded.
Over the past week, the price has changed by -3.92%, over one month by -5.11%, over three months by -7.77% and over the past year by -6.19%.

Is NVST a buy, sell or hold?

Envista Holdings has received a consensus analysts rating of 3.29. Therefor, it is recommend to hold NVST.

Strong Buy: 3
Buy: 0
Hold: 10
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the NVST price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	22	15.1%
Analysts Target Price	22	15.1%
ValueRay Target Price	16.5	-13.7%

NVST Fundamental Data Overview November 21, 2025

Market Cap USD = 3.15b (3.15b USD * 1.0 USD.USD)
P/E Trailing = 210.5556
P/E Forward = 15.4083
P/S = 1.2011
P/B = 1.009
Beta = 1.03
Revenue TTM = 2.62b USD
EBIT TTM = 218.6m USD
EBITDA TTM = 341.9m USD
Long Term Debt = 1.45b USD (from longTermDebt, last quarter)
Short Term Debt = 39.2m USD (from shortTermDebt, last quarter)
Debt = 1.60b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 468.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.62b USD (3.15b + Debt 1.60b - CCE 1.13b)
Interest Coverage Ratio = 3.09 (Ebit TTM 218.6m / Interest Expense TTM 70.8m)
FCF Yield = 7.26% (FCF TTM 262.5m / Enterprise Value 3.62b)
FCF Margin = 10.01% (FCF TTM 262.5m / Revenue TTM 2.62b)
Net Margin = 0.58% (Net Income TTM 15.3m / Revenue TTM 2.62b)
Gross Margin = 55.37% ((Revenue TTM 2.62b - Cost of Revenue TTM 1.17b) / Revenue TTM)
Gross Margin QoQ = 55.26% (prev 54.27%)
Tobins Q-Ratio = 0.64 (Enterprise Value 3.62b / Total Assets 5.64b)
Interest Expense / Debt = 2.72% (Interest Expense 43.6m / Debt 1.60b)
Taxrate = 160.7% (out of range, set to none) (80.2m / 49.9m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.37 (Total Current Assets 1.95b / Total Current Liabilities 821.7m)
Debt / Equity = 0.52 (Debt 1.60b / totalStockholderEquity, last quarter 3.09b)
Debt / EBITDA = 1.37 (Net Debt 468.2m / EBITDA 341.9m)
Debt / FCF = 1.78 (Net Debt 468.2m / FCF TTM 262.5m)
Total Stockholder Equity = 3.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.27% (Net Income 15.3m / Total Assets 5.64b)
RoE = 0.50% (Net Income TTM 15.3m / Total Stockholder Equity 3.05b)
RoCE = 4.86% (EBIT 218.6m / Capital Employed (Equity 3.05b + L.T.Debt 1.45b))
RoIC = 5.93% (EBIT 218.6m / (Assets 5.64b - Curr.Liab 821.7m - Cash 1.13b))
WACC = 7.09% (E(3.15b)/V(4.75b) * Re(10.70%) + (debt cost/tax rate unavailable))
Discount Rate = 10.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.41%
[DCF Debug] Terminal Value 71.24% ; FCFE base≈266.6m ; Y1≈299.0m ; Y5≈398.9m
Fair Price DCF = 27.40 (DCF Value 4.51b / Shares Outstanding 164.4m; 5y FCF grow 14.07% → 3.0% )
EPS Correlation: -50.87 | EPS CAGR: -16.18% | SUE: 0.56 | # QB: 0
Revenue Correlation: 12.66 | Revenue CAGR: 0.50% | SUE: 1.59 | # QB: 3

Additional Sources for NVST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle